 Secondary Objectives: 1 To compare LNG IUD safety to the safety of the C-IUD with respect to HIV progression as measured by changes in plasma viral load VL at 6 months between the two pre-ART study arms. 2 To explore LNG IUD safety with respect to non-HIV related outcomes, including hemoglobin change, incidence of sexually-transmitted infections STIs and pelvic inflammatory disease PID. 3 To measure LNG IUD acceptability through device continuation and other measures for the LNG IUD as compared to the C-IUD. 4 To compare three genital tract sampling methods to determine which provides optimal recovery of HIV RNA and immune mediators over a series of three visits. 